Press Releases

Date Title and Summary Additional Formats
Toggle Summary Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cystic Fibrosis View HTML
Toggle Summary Anthera Pharmaceuticals to Present at Rodman & Renshaw's 18th Annual Global Investment Conference View HTML
Toggle Summary Anthera Pharmaceuticals to Participate in the Citi 12th Annual Biotech Conference View HTML
Toggle Summary Anthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy View HTML
Toggle Summary Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network View HTML
Toggle Summary Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy View HTML
Toggle Summary Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results View HTML
Toggle Summary Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development Network View HTML
Toggle Summary Anthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura View HTML
Toggle Summary Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura View HTML